Profile data is unavailable for this security.
About the company
Editas Medicine, Inc. is a clinical-stage gene editing company. The Company is focused on developing transformative gene editing medicines to treat a range of serious diseases. It has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The Company is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The Company's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.
- Revenue in USD (TTM)25.64m
- Net income in USD-201.13m
- LocationEditas Medicine Inc11 Hurley StCAMBRIDGE 02141-2110United StatesUSA
- Phone+1 (617) 401-9000
- Fax+1 (302) 655-5049